Previous 10 | Next 10 |
- More than 1,400 subjects randomized - - Satsuma expects to announce topline SUMMIT trial results in Q4 2022 - SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company deve...
SOUTH SAN FRANCISCO, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatmen...
SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatmen...
Gainers: Yumanity Therapeutics YMTX +46%. Babylon (BBLN) +11%. Sema4 (SMFR) +11%. Nano-X Imaging (NNOX) +10%. Satsuma Pharmaceuticals (STSA) +10%. Losers: Praxis Precision Medicines PRAX -63%. eFFECTOR Therapeutics (EFTR) -20%. Pear Therapeutics (PEAR) ...
SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment...
Satsuma Pharmaceuticals press release (NASDAQ:STSA): Q1 GAAP EPS of -$0.49 in-line. $80.6 million in cash, cash equivalents and marketable securities as of March 31, 2022, provides runway into second half of 2023 For further details see: Satsuma Pharmaceuticals GAAP EPS of -$0.49 in-lin...
- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing and on track to read out topline results in Q4 2022 - - New Drug Application (NDA) submission anticipated in Q1 2023 - - $80.6 million in cash, cash equivalents and marketable securities as of March 31, 2022, prov...
Satsuma Pharmaceuticals press release (NASDAQ:STSA): Q4 GAAP EPS of -$0.49. As of December 31, 2021, Satsuma had $95.8 million in combined cash, cash equivalents and marketable securities. For further details see: Satsuma Pharmaceuticals GAAP EPS of -$0.49
- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing; key trial on track to read out topline results in Q4 2022 - - $95.8 million in cash, cash equivalents and marketable securities as of December 31, 2021, provides runway into second half of 2023 - SOUTH SAN FRANCISC...
SOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatme...
News, Short Squeeze, Breakout and More Instantly...
Satsuma Pharmaceuticals Inc. Company Name:
STSA Stock Symbol:
NYSE Market:
DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. , a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic produc...
January 2024 PDUFA date expected If approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S. Food and Drug Administration (FDA) and International Headache Society ...
NEW YORK, NY / ACCESSWIRE / May 1, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hoth Therapeutics, Inc. (NASDAQ:HOTH)'s...